Associated Papers
Anaplastic lymphoma kinase inhibitors-a review of anticancer properties, clinical efficacy, and resistance mechanisms.
Kiełbowski K et al.
Frontiers in Pharmacology, 2023
A computational examination of the therapeutic advantages of fourth-generation ALK inhibitors TPX-0131 and repotrectinib over third-generation lorlatinib for NSCLC with ALK F1174C/L/V mutations.
Balasundaram A et al.
Frontiers in Molecular Biosciences, 2023
Durable clinical response to ALK tyrosine kinase inhibitors in ALK-rearranged non-small cell lung cancer: a case report.
Hu H et al.
Translational Cancer Research, 2022
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
Tan DS et al.
Lung Cancer (amsterdam, Netherlands), 2022
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.
Christopoulos P et al.
Translational Lung Cancer Research, 2021
34164264 (PubMed )
Supplement: tlcr-10-05-2118-supplementary.pdf
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S et al.
Ebiomedicine, 2020
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2019
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.
Santarpia M et al.
Drug Design, Development and Therapy, 2017
Select a paper to view details